99 results
8-K
EX-99.1
EQ
Equillium Inc
9 May 24
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
4:05pm
research and development tax incentive credits.
General and administrative (G&A) expenses were $3.7 million for each of the three-month periods ended March
S-8
EX-5.1
wi1vgrq ama9
25 Mar 24
Registration of securities for employees
4:26pm
S-8
oc96zsius9
25 Mar 24
Registration of securities for employees
4:26pm
S-8
9ydo8vnbayxfe5whs2
25 Mar 24
Registration of securities for employees
4:26pm
8-K
oyi46z6
8 Mar 24
Departure of Directors or Certain Officers
4:01pm
8-K
EX-99.1
aaa39
8 Mar 24
Departure of Directors or Certain Officers
4:01pm
8-K
EX-99.2
sp21s a0o2ou
8 Nov 23
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
4:05pm
8-K
EX-1.1
jd3 ukcjft
5 Oct 23
Entry into a Material Definitive Agreement
5:28pm
424B5
8b21o90g2j vm5go
5 Oct 23
Prospectus supplement for primary offering
5:23pm
8-K
EX-99.1
aezgjux2fy63q rzq
9 Aug 23
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
4:06pm
8-K
EX-99.1
j0str4s0 j9b1
11 May 23
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
4:06pm